• Company
• Atopic dermatitis drug Ebglyss to enter Korea next year
• by Whang, byung-woo Oct 31, 2024 05:55am

• Company
• Oral ALS drug 'Radicava' likely to land in KOR
• by Eo, Yun-Ho Oct 31, 2024 05:55am

• Company
• Pfizer's Q3 sales 31%↑amid increased demand for COVID-19
• by Son, Hyung Min Oct 31, 2024 05:55am

• Company
• NIP inclusion of HPV vaccines on the horizon
• by Whang, byung-woo Oct 31, 2024 05:55am

• Company
• Difficulty expanding indications for antibody-drug conjugate
• by Moon, sung-ho Oct 30, 2024 05:54am

• Company
• Dupixent sales skyrocket with 'expanded indications'
• by Son, Hyung Min Oct 30, 2024 05:54am

• Company
• "Early intervention" needed for treating multiple myeloma
• by Whang, byung-woo Oct 29, 2024 05:49am

• Company
• Will the third time be the charm for Mylotarg?
• by Eo, Yun-Ho Oct 29, 2024 05:49am

• Company
• ABL Bio receives ₩7B as milestone payment from Sanofi
• by Kim, Jin-Gu Oct 29, 2024 05:49am

• Company
• 'Aquipta,' new oral migraine drug, can be prescribed
• by Eo, Yun-Ho Oct 28, 2024 05:53am